biostudies-literatureUnknown53Tuxen A<h4>Background</h4>This study investigated excess risk in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) with or without elevated levels of NT-proBNP (N-terminal pro-brain natriuretic peptide).<h4>Methods</h4>Patients with HFrEF from the NorthStar cohort (n = 1120) were matched on age, sex, and presence of AF (atrial fibrillation/flutter) to five controls without HFrEF from The Danish National Patient Registries. Patients were compared with controls before and after stratification according to baseline NT-proBNP levels, with cutoffs defined as </≥ 600 pg/ml in patients with sinus rhythm and </≥ 900 pg/ml in patients with AF. The primary composite endpoint was a 7-year risk of cardiovascular death or HF admission.<h4>Results</h4>In the HFrEF cohort, 704 International journal of cardiology. Heart & vasculature101441https://www.ebi.ac.uk/biostudies/studies/S-EPMC11368590biostudies-literatureExcess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).PMC11368590Koeber LNouravesh NGustafsson FFoesbol ESchou MVidebaek LMalik MZahir DButt JHMalmborg MJensen JAndersson CTuxen AAndersen CFfalseExcess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).<h4>Background</h4>This study investigated excess risk in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) with or without elevated levels of NT-proBNP (N-terminal pro-brain natriuretic peptide).<h4>Methods</h4>Patients with HFrEF from the NorthStar cohort (n = 1120) were matched on age, sex, and presence of AF (atrial fibrillation/flutter) to five controls without HFrEF from The Danish National Patient Registries. Patients were compared with controls before and after stratification according to baseline NT-proBNP levels, with cutoffs defined as </≥ 600 pg/ml in patients with sinus rhythm and </≥ 900 pg/ml in patients with AF. The primary composite endpoint was a 7-year risk of cardiovascular death or HF admission.<h4>Results</h4>In the HFrEF cohort, 704 2024-01-01T00:00:00Z2024 Aug2025-06-01T03:24:58.046Z2024-11-15T21:28:48.358ZS-EPMC113685903922897710.1016/j.ijcha.2024.101441